tbuckley/cabot-search huggingface dataset:
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Authors: Celeste Lebbé, Nicolas Meyer, Laurent Mortier, Ivan Marquez-Rodas, Caroline Robert, Piotr Rutkowski, Alexander M. Menzies, Thomas Eigentler, Paolo A. Ascierto, Michael Smylie, Dirk Schadendorf, Mazhar Ajaz, Inge Marie Svane, Rene Gonzalez, Linda Rollin, Jennifer Lord-Bessen, Abdel Saci, Elena Grigoryeva, Jacopo Pigozzo
Journal: Journal of Clinical Oncology (2019)

PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1) improves the safety profile of the combination. PATIENTS AND METHODS Patients (N = 360) age 18 years or older with previously untreated, unresectable stage III or IV melanoma were randomly assigned 1:1 to NIVO3+IPI1 or NIVO1+IPI3 once every 3 weeks for four doses. After 6 weeks, all patients received NIVO 480 mg once every 4 weeks until disease progression or unacceptable toxicity. The primary end point was a comparison of the incidence of treatment-related grade 3 to 5 adverse events (AEs) between groups. Secondary end points included descriptive analyses of objective response rate, progression-free survival, and overall survival. The study was not designed to formally demonstrate noninferiority of NIVO3+IPI1 to NIVO1+IPI3 for efficacy end points. RESULTS At a minimum follow-up of 12 months, incidence of treatment-related grade 3 to 5 AEs was 34% with NIVO3+IPI1 versus 48% with NIVO1+IPI3 ( P = .006). In descriptive analyses, objective response rate was 45.6% in the NIVO3+IPI1 group and 50.6% in the NIVO1+IPI3 group, with complete responses in 15.0% and 13.5% of patients, respectively. Median progression-free survival was 9.9 months in the NIVO3+IPI1 group and 8.9 months in the NIVO1+IPI3 group. Median overall survival was not reached in either group. CONCLUSION The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3-5 AEs with NIVO3+IPI1 versus NIVO1+IPI3. Descriptive analyses showed that there were no meaningful differences between the groups for any efficacy end point, although longer follow up may help to better characterize efficacy outcomes.
ECG Response: February 23, 2016
Authors: Philip Podrid
Journal: Circulation (2016)

ECG Challenge Response 764ECG Challenge: A 47-year-old woman with a history of palpitations that occur after exercise presents to an emergency department with palpitations that have persisted for several hours.An ECG (A) is obtained.Several minutes later the palpitations abruptly stop and an ECG (B) is repeated.
Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017
Authors: Michael Edelstein, Nalini Iyanger, Nicola Hennessy, David Mesher, Marta Checchi, Kate Soldan, Mark McCall, Julie Nugent, Jonathan Crofts, Janice Lo, Richard Gilson, Karen Powell, Mary Ramsay, Joanne Yarwood
Journal: Eurosurveillance (2019)

Background: Opportunistic human papillomavirus (HPV) vaccination for men who have sex with men (MSM) was piloted in sexual health clinics (SHC) in England between 2016 and 2018. Aim: to evaluate the pilot’s first year (April 2016–March 2017) in terms of feasibility, acceptability, uptake, impact and equity and interpret the outcome in the context of wide HPV vaccination policy. Methods: Attendance and uptake data from routine SHC surveillance datasets and a cross-sectional survey administered to individuals receiving the vaccine were analysed. Results: Among 18,875 eligible MSM, 8,580 (45.5%) were recorded as having received one HPV vaccine dose, decreasing slightly with increasing age, and uptake was higher in rural than urban areas. Survey results suggested that of those receiving the first dose of HPV vaccine, 8% were new attendees and that among those, less than 11% attended just to receive the vaccine. Of those having their first HPV vaccination, 95% indicated they would like to receive the next vaccine doses at the same clinic and 85% of patients reported accessing other services when visiting SHC for the first dose of vaccine. Conclusion: An opportunistic HPV vaccination programme for MSM can be delivered in an acceptable and, as far as can be evaluated, equitable manner, without major disruption to SHC and HIV clinics.
Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population
Authors: Belén Navarro, Juan Manuel Sancho, Silvina Grasso Cicala, Mario Spione, Begoña Soler, Pier Luigi Zinzani
Journal: Blood (2018)
Big Data From Health Records in Mental Health Care
Authors: Gregory E. Simon
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Cancer statistics for Hispanics/Latinos, 2015
Authors: Rebecca L. Siegel, Stacey A. Fedewa, Kimberly D. Miller, Ann Goding‐Sauer, Paulo S. Pinheiro, Dinorah Martinez‐Tyson, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2015)

Cancer is the leading cause of death among Hispanics/Latinos, who represent the largest racial/ethnic minority group in the United States, accounting for 17.4% (55.4 million/318 million) of the total US population in 2014. Every 3 years, the American Cancer Society reports on cancer statistics for Hispanics based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Among Hispanics in 2015, there will be an estimated 125,900 new cancer cases diagnosed and 37,800 cancer deaths. For all cancers combined, Hispanics have 20% lower incidence rates and 30% lower death rates compared with non-Hispanic whites (NHWs); however, death rates are slightly higher among Hispanics during adolescence (aged 15-19 years). Hispanic cancer rates vary by country of origin and are generally lowest in Mexicans, with the exception of infection-associated cancers. Liver cancer incidence rates in Hispanic men, which are twice those in NHW men, doubled from 1992 to 2012; however, rates in men aged younger than 50 years declined by 43% since 2003, perhaps a bellwether of future trends for this highly fatal cancer. Variations in cancer risk between Hispanics and NHWs, as well as between subpopulations, are driven by differences in exposure to cancer-causing infectious agents, rates of screening, and lifestyle patterns. Strategies for reducing cancer risk in Hispanic populations include increasing the uptake of preventive services (e.g., screening and vaccination) and targeted interventions to reduce obesity, tobacco use, and alcohol consumption.
Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation - the Help-ECMO Pilot Randomised Controlled Trial
Authors: Zoe McQuilten, Cecile Aubron, Michael Bailey, Jasmin Board, Heidi Buhr, Mark Dennis, Paul Forrest, David McIlroy, Lynnette Murray, Deirdre Murphy, Vincent Pellegrino, David Pilcher, Jayne Sheldrake, Huyen Tran, Shirley Vallance, David Jamie Cooper
Journal: Blood (2016)
Nationwide Introduction of Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer and Its Association With Severe Complications
Authors: Siv Lykke Jørgensen, Ole Mogensen, Chunsen Wu, Ken Lund, Maria Iachina, Malene Korsholm, Pernille Tine Jensen
Journal: JAMA Surgery (2019)

Minimally invasive laparoscopic surgery (MILS) for endometrial cancer reduces surgical morbidity compared with a total abdominal hysterectomy. However, only a minority of women with early-stage endometrial cancer undergo MILS.
Abstract 2806: CD146, a suppressor of breast cancer, is a novel target of CD44-signaling.
Authors: Allal Ouhtit, Mohamed E. Abdraboh, Andrew D. Hollenbach, Ishita Gupta, Somya Shanmuganathan, Madhwa HG Raj
Journal: Cancer Research (2013)

Abstract Cancer cell invasion and metastasis is the worst aspect of cancer, and disruption in the cell adhesion molecules (CAM) represents the initiating event in tumor cell invasion. While the hyaluronan receptor CD44 promotes breast cancer (BC) metastasis, CD146 is a melanoma CAM that appears to suppress BC (although it promotes other cancers). In addition, the molecular mechanism by which CD146 suppresses BC is still unclear. To shed light on this discrepancy, we initially used subtractive hybridization combined with northern blotting, and identified CD146 as a potential downstream target of CD44-signaling in the MDA-435 BC cell line. Here, we provide both structural and functional evidence indicating that CD146 is a downstream target for CD44, in a way that CD146 expression is regulated according to tumor microenvironment. Finally, this study demonstrates a new role for CD44 in regulating neovascularization and promoting cancer cell transmigration of blood vessels via CD146. Citation Format: Allal Ouhtit, Mohamed E. Abdraboh, Andrew D. Hollenbach, Ishita Gupta, Somya Shanmuganathan, Madhwa HG Raj. CD146, a suppressor of breast cancer, is a novel target of CD44-signaling. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2806. doi:10.1158/1538-7445.AM2013-2806
Case-Control Studies—Reply
Authors: Telba Z. Irony
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
18F FDG Uptake Due to Late-Onset Osteoradionecrosis for Tongue Base Carcinoma
Authors: Kanchan P. Dholam, Gurkaran Preet Singh, Jai Prakash Agarwal, Abhishek Mahajan
Journal: Clinical Nuclear Medicine (2019)

Differentiating osteoradionecrosis (ORN) from tumor recurrence is challenging. This report is rare documentation of false-positive F-FDG PET scan attributed to ORN in a patient previously treated for carcinoma of base of tongue (Ca BOT). Extraordinarily high F-FDG uptake was seen in right ramus (SUVmax, 17.4), left body mandible (SUVmax, 13.6) with left pleural deposits (SUVmax, 17.4). Tumor recurrence was suspected. Pleural fluid aspirate showed evidence of metastatic disease. However, CT-guided biopsy of mandibular lesions revealed necrotic tissue. Hence diagnosis of ORN was established. Patient was put on palliative chemotherapy. No mandibular recurrence was noted during 6-month follow-up period.
Abstract P3-09-10: Withdrawn
Authors: M Pollán, V Lope, B Pérez-Gómez, AJ Molina, A Tardón, M Díaz-Santos, E Ardanaz, C O'Callhagan, JM Altzibar, I Gómez-Acebo, V Moreno, R Peiró, R Marcos-Grajera, M Kogevinas, N Aragonés, G López-Abente, J García-Pérez
Journal: Cancer Research (2018)

Abstract This abstract was withdrawn by the authors.
2018 Update on Pediatric Medical Overuse
Authors: Eric R. Coon, Ricardo A. Quinonez, Daniel J. Morgan, Sanket S. Dhruva, Timmy Ho, Nathan Money, Alan R. Schroeder
Journal: JAMA Pediatrics (2019)

<h3>Importance</h3> Efforts to combat medical overuse have gained traction in recent years, but success has been intermittent and shortcomings have been recognized. A commitment to a strong evidence base is needed to more broadly engage clinicians and reduce overuse. <h3>Observations</h3> A structured MEDLINE search and a manual review of tables of contents from selected high-impact journals was performed to identify original research published in 2017 relevant to pediatric overuse. Articles were scored from low to high for 3 categories: quality of methods, magnitude of potential harm, and number of patients potentially harmed. The top-scoring articles presented in this review highlight examples of safe reductions in treatment intensity, including in the setting of cancer, appendicitis, acute respiratory tract infection, and elective anesthesia. This year's articles also provide cautionary examples of rational interventions adopted without a full understanding of potential harms, including pharmacologic migraine therapies, docosahexaenoic acid supplementation for preterm neonates, tight glycemic control for individuals with critically illness, and prophylactic antibiotics for children with vesicoureteral reflux. <h3>Conclusions and Relevance</h3> The articles represent high-quality, original research from 2017 that may help mitigate overuse. These works should be fundamental to the maturation of the pediatric overuse field.
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
Authors: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, Heather H. Cheng, Mario A. Eisenberger, Alan H. Bryce, Michael T. Schweizer, Emmanuel S. Antonarakis
Journal: European Urology (2019)
Letter to the Editor: Tuberculosis and Antituberculosis Treatments Cannot Be Ignored When Evaluating Patients With Cirrhosis Who Are Coinfected With HIV or Not
Authors: RuiLing Wang, Peng Zhu
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To the Editor: The study conducted by Salmon‐Ceron et al.1 shows that in the period of combined antiretroviral therapy, the risks of hepatocellular carcinoma (HCC) and hepatic decompensation are similar between hepatitis C virus (HCV) monoinfected patients with cirrhosis and human immunodeficiency virus (HIV)/HCV coinfected patients with cirrhosis, even though the latter have higher all‐cause mortality. Although rigorously implemented, the study overlooked tuberculosis infections and antituberculosis therapy, which may greatly influence the outcome. First, it is well known that HIV‐infected patients are more susceptible to tuberculosis. Gao et al.2 reported that the prevalence of tuberculosis in HIV‐positive patients ranges from 2.9% to 64.5%, of which 31.25% are in Africa, 17.21% are in Asia, 20.11% are in Europe, and 14.84% are in the United States. Meanwhile, according to the World Health Organization,3 the tuberculosis infection accounted for approximately 26% deaths of HIV‐infected patients. In addition, the prevalence of tuberculosis in people with cirrhosis is 15 times higher than the general population, as cirrhosis is an independent risk factor of tuberculosis.4 Second, antituberculosis drugs can accelerate HCC development and cause acute liver failure in cirrhosis because of their potential hepatotoxicity.4 Lim et al.5 identified that long‐term (more than 12 months) use of isoniazid, rifampicin, or the combination of the two led to significantly higher risk of HCC, with an odds ratio of 3.51 (95% confidence interval [CI], 2.11‐5.84), 4.17 (95% CI, 2.76‐4.31), and 7.17 (95% CI, 4.08‐12.6), respectively. Similarly, higher risk of HCC was also observed in patients with cirrhosis with treatment of high doses (>16,050 mg/year) of isoniazid and rifampicin than those without antituberculosis treatment. Lim et al.’s study demonstrated that patients with cirrhosis receiving long‐term, high‐dose isoniazid and rifampicin treatment, especially the combination of the two, have a higher rise of HCC. In summary, HIV infection and cirrhosis are risk factors of tuberculosis infection. Tuberculosis infection and antituberculosis treatment have a significant impact on the all‐cause mortality, the incidence of HCC, and the decompensation of cirrhosis. From our perspective, the tuberculosis infection and antituberculosis treatment may differ between the HIV‐infected group and the noninfected group. Therefore, the conclusion will be more convincing if the research could provide more detailed information about tuberculosis infection and antituberculosis treatments, and optimize the previous findings.
Clinics Aim to Improve Post-ICU Recovery
Authors: Bridget M. Kuehn
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Authors: Dongdong Feng, Phung Gip, Kelly Marie McKenna, Feifei Zhao, Ofelia Mata, Timothy S Choi, Jiaqi Duan, Kavitha Sompalli, Ravi Majeti, Irving L Weissman, Chris H Takimoto, Mark Ping Chao, James Y Chen, Jie Liu, Jens-Peter Volkmer
Journal: Blood (2018)
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
Authors: Claudia Maletzki, Leonie Wiegele, Ingy Nassar, Jan Stenzel, Christian Junghanss
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Mismatch Repair Deficiency (MMR-D)-related tumors are highly immunogenic and constitute ideal vaccination targets. In a proof-of-concept study delayed tumorigenesis and prolonged survival has been shown in a clinically-relevant mouse model for MMR-D-related diseases (=MLH1 knock out mice). To refine this approach, vaccination was combined with immune modulatory low-dose chemotherapy to polarize immune regulatory subtypes. <h3>Methods</h3> Mice (prophylactic: 8–10 weeks; therapeutic: &gt; 36 weeks) received a single injection of cyclophosphamide (CPX, 120 mg/kg bw, i.p.) or gemcitabine (GEM, 100 mg/kg bw, i.p.) prior to vaccination (lysate of a gastrointestinal tumor allograft, 10 mg/kg bw, <i>n</i> = 9 mice/group). The vaccine was given repetitively (10 mg/kg bw, s.c., 4 x / once a week, followed by monthly boosts) until tumor formation or progression. Tumor growth ([<sup>18</sup>F] FDG PET/CT imaging) and immune responses were monitored (flow cytometry, IFNγ ELISpot). The microenvironment was analyzed by immunofluorescence. <h3>Results</h3> Prophylactic application of GEM + lysate delayed tumorigenesis compared to lysate monotherapy and CPX-pre-treatment (median time of onset: 53 vs. 47 vs. 48 weeks). 33% of mice even remained tumor-free until the experimental endpoint (= 65 weeks). This was accompanied by long-term effect on cytokine plasma levels; splenic myeloid derived suppressor cells (MDSC) as well as regulatory T cell numbers. Assessment of tumor microenvironment from GEM + lysate treated mice revealed low numbers of MDSCs, but enhanced T cell infiltration, in some cases co-expressing PD-L1. Therapeutic chemo-immunotherapy (GEM + lysate) had minor impact on overall survival (median time: 12 (GEM + lysate) vs. 11.5 (lysate) vs. 3 weeks (control)), but induced complete remission in one case. Dendritic and T cell infiltrates increased in both treatment groups. Reactive T cells specifically recognized MLH1<sup>−/−</sup> tumor cells in IFNγ ELISpot, but lacked response towards NK cell targets YAC-1. <h3>Conclusions</h3> Combined chemo-immunotherapy impairs tumor onset and growth likely attributable to modulation of immune responses. Depleting or 're-educating' immunosuppressive cell types, such as MDSC, may help moving a step closer to combat cancer.
Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B‐cell lymphoma presenting as AL amyloidoma of the skin
Authors: A. Dangien, M. Beylot‐Barry, M. Battistella, C. Ram‐Wolff, A. Talbot, M. Rybojad, B. Vergier, M. Jachiet, J.‐D. Bouaziz, B. Arnulf, M. Bagot, A. Masson
Journal: British Journal of Dermatology (2019)
Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?
Authors: Muthiah Vaduganathan, Ayman Samman Tahhan, Alaaeddin Alrohaibani, Stephen J. Greene, Gregg C. Fonarow, Orly Vardeny, JoAnn Lindenfeld, Mariell Jessup, Mona Fiuzat, Christopher M. O’Connor, Javed Butler
Journal: JACC Heart Failure (2019)
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial
Authors: Azfar Zaman, Robbert J de Winter, Norihiro Kogame, Chun Chin Chang, Rodrigo Modolo, Ernest Spitzer, Pim Tonino, Sjoerd Hofma, Aleksander Zurakowski, Pieter C Smits, Janusz Prokopczuk, Raul Moreno, Anirban Choudhury, Ivo Petrov, Angel Cequier, Neville Kukreja, Angela Hoye, Andrés Iniguez, Imre Ungi, Antonio Serra, Robert J Gil, Simon Walsh, Gincho Tonev, Anthony Mathur, Bela Merkely, Antonio Colombo, Sander Ijsselmuiden, Osama Soliman, Upendra Kaul, Yoshinobu Onuma, Patrick W Serruys
Journal: The Lancet (2019)